The Oncology Institute achieved $100 million in revenue for Q4 2024, representing a 16.9% year-over-year increase. Dispensary revenue saw significant growth, while patient services declined due to the loss of a major contract. The company reported a net loss of $13.2 million for the quarter and continues to improve operational efficiency and cash flow.
Generated $100 million in revenue, up 16.9% from Q4 2023.
Patient services revenue declined 10.6% year-over-year due to a lost contract.
Dispensary revenue increased by 72.4% year-over-year, driven by California pharmacy performance.
Reported a net loss of $13.2 million for the quarter.
For fiscal year 2025, The Oncology Institute projects revenue between $460 million and $480 million, with improved gross profit and operational efficiency despite seasonal challenges.
Visualization of income flow from segment revenue to net income